Novartis has partnered with Vancouver-based Clarius Mobile Health to improve early detection of psoriatic arthritis (PsA) in Canada. PsA is a chronic autoimmune disease causing joint inflammation and often associated with psoriasis. The collaboration provides rheumatologists with Clarius’ handheld ultrasound devices and comprehensive training.
Novartis will evaluate the adoption and impact of ultrasound usage in routine practice. Clarius, recognized for miniaturizing ultrasound technology, connects devices to smartphones and tablets, enhancing real-time medical imaging. This partnership could transform PsA care and expand to other conditions.
Want to know more? Check out the source code on Techcouver.com.